Therapeutic Advances in Medical Oncology,
Journal Year:
2023,
Volume and Issue:
15
Published: Jan. 1, 2023
Despite
key
advances
in
the
treatment
of
prostate
cancer
(PCa),
a
proportion
men
have
de
novo
resistance,
and
all
will
develop
resistance
to
current
therapeutics
over
time.
Aberrant
lipid
metabolism
has
long
been
associated
with
carcinogenesis
progression,
but
more
recently
there
an
explosion
preclinical
clinical
data
which
is
informing
new
trials.
This
review
explores
epidemiological
links
between
obesity
metabolic
syndrome
PCa,
evidence
for
altered
circulating
lipids
PCa
their
potential
role
as
biomarkers,
well
novel
therapeutic
strategies
targeting
including
therapies
widely
used
cardiovascular
disease
such
statins,
metformin
lifestyle
modification,
targeted
agents
sphingosine
kinase
inhibitors,
DES1
inhibitors
FASN
beta
oxidation.
Antioxidants,
Journal Year:
2023,
Volume and Issue:
12(6), P. 1163 - 1163
Published: May 27, 2023
Mitochondrial
fission
is
a
crucial
process
in
maintaining
metabolic
homeostasis
normal
physiology
and
under
conditions
of
stress.
Its
dysregulation
has
been
associated
with
several
diseases,
including,
but
not
limited
to,
obesity,
type
2
diabetes
(T2DM),
cardiovascular
diseases.
Reactive
oxygen
species
(ROS)
serve
vital
role
the
genesis
these
conditions,
mitochondria
are
both
main
sites
ROS
production
primary
targets
ROS.
In
this
review,
we
explore
physiological
pathological
roles
mitochondrial
fission,
its
regulation
by
dynamin-related
protein
1
(Drp1),
interplay
between
health
We
also
discuss
potential
therapeutic
strategies
targeting
through
antioxidant
treatments
for
ROS-induced
including
effects
lifestyle
interventions,
dietary
supplements,
chemicals,
such
as
division
inhibitor-1
(Mdivi-1)
other
inhibitors,
well
certain
commonly
used
drugs
This
review
highlights
importance
understanding
approach
to
protecting
against
conditions.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(4), P. 3710 - 3710
Published: Feb. 13, 2023
Hepatocellular
carcinoma
is
today
the
sixth
leading
cause
of
cancer-related
death
worldwide,
despite
decreased
incidence
chronic
hepatitis
infections.
This
due
to
increased
diffusion
metabolic
diseases
such
as
syndrome,
diabetes,
obesity,
and
nonalcoholic
steatohepatitis
(NASH).
The
current
protein
kinase
inhibitor
therapies
in
HCC
are
very
aggressive
not
curative.
From
this
perspective,
a
shift
strategy
toward
may
represent
promising
option.
Here,
we
review
knowledge
on
dysregulation
therapeutic
approaches
targeting
pathways.
We
also
propose
multi-target
approach
possible
new
option
pharmacology.
Therapeutic Advances in Medical Oncology,
Journal Year:
2023,
Volume and Issue:
15
Published: Jan. 1, 2023
Despite
key
advances
in
the
treatment
of
prostate
cancer
(PCa),
a
proportion
men
have
de
novo
resistance,
and
all
will
develop
resistance
to
current
therapeutics
over
time.
Aberrant
lipid
metabolism
has
long
been
associated
with
carcinogenesis
progression,
but
more
recently
there
an
explosion
preclinical
clinical
data
which
is
informing
new
trials.
This
review
explores
epidemiological
links
between
obesity
metabolic
syndrome
PCa,
evidence
for
altered
circulating
lipids
PCa
their
potential
role
as
biomarkers,
well
novel
therapeutic
strategies
targeting
including
therapies
widely
used
cardiovascular
disease
such
statins,
metformin
lifestyle
modification,
targeted
agents
sphingosine
kinase
inhibitors,
DES1
inhibitors
FASN
beta
oxidation.
